Development of a lung immune prognostic index-based nomogram model for predicting overall survival and immune-related adverse events in non-small cell lung cancer patients treated with sintilimab

BackgroundSintilimab, a programmed cell death protein-1 (PD-1) inhibitor, has shown efficacy in non-small cell lung cancer (NSCLC), though response heterogeneity persists. Previous studies suggest that the Lung Immune Prognostic Index (LIPI) may predict prognosis and immune-related adverse events (i...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Jian Xu, Tingting Peng, Kaikai Fan, Yuxiao Dou, Lingti Kong, Ran Sang
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2025-05-01
סדרה:	Frontiers in Immunology
נושאים:	nomograms non-small cell lung cancer immunotherapy inflammation markers predicting sintilimab
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1569689/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!